Leveraging Innovation To Deliver Precision Medicines

Jubilant Therapeutics

Jubilant Therapeutics is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases.

Our Strategy

Focus on unmet medical needs resulting from specific genetic mutations, drug resistance, or compensatory mechanisms

Build a portfolio of internally discovered and selectively acquired programs structured into asset-based subsidiaries

Fast track promising assets from discovery to clinical proof of concept

Advance programs into pivotal studies and commercialization through creative partnerships

Leverage proven and synergistic capabilities of Jubilant Pharmova's world-class research with in-house development expertise


10th – 15th April, 17th – 21st May 2021

American Association of Cancer Research (AACR) Annual Meeting 2021

Poster Presentation

Novel, small molecule PRMT5 Inhibitors for treatment of cancer

Novel, heterocyclic small molecule inhibitors of PD-1/PD-L1 pathway


We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.